Biomedical Engineering Reference
In-Depth Information
Drugs analyzed
sample
Analytical method
LOQ (ng/ml)
(% bias)
(CV%)
Reference
Vatalanib
50 m l Human plasma
ESI-TSQ
10.2
6.25
8.38
Lankheet et al. [
119
]
Axitinib
100 m l Human plasma
ESI-TSQ
0.2
-
-
Sparidans et al. [
120
]
Neratinib
250 m l Human plasma
ESI-TSQ
3
Abbas et al. [
87
]
Vandetanib
100 ml Human plasma
100 ml Human CSF
Turbo ion
spray-TSQ
1
0.25
8.5
−0.2
3.4
2.6
Bai et al. [
118
]
Imatinib,
dasatinib,
nilotinib
250 ml Human plasma
ESI-single
quadrupole
78.1
62.5
62.5
-
-
De Francia et al. [
133
]
Imatinib
Erlotinib
Ge fi tinib
100 m l Human plasma
ESI-TSQ
4.4
4.5
4.8
−3.8 to 10.6
2.1 to 3.2
Chahbouni et al. [
135
]
Imatinib, dasatinib,
nilotinib,
sunitinib,
sorafenib, and
lapatinib
100 ml Human plasma
ESI-TSQ
1-10
−6.3 to 6.7
3.4 to 9.9
Haouala et al. [
122
]
Erlotinib, imatinib,
lapatinib,
nilotinib,
sorafenib, and
sunitinib
100 m l Human plasma
ESI-TSQ
2.2 for
sunitinib
3.8-12.6 for
other TKI
Gotze et al. [
137
]
Bosutinib, erlotinib,
ge fi tinib, and
vemurafenib
ESI-TSQ
1, 10, 10, and
80, resp.
Neeman [
139
]
Dasatinib and
lapatinib
5 × 10
4
cells/mL lung cancer
cell-lines
ESI-TSQ
50
100
-
8
13
Roche et al. [
141
]
(continued)
